Browse recruiting and upcoming clinical trials for ATTRv amyloidosis.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults 18–80 with biopsy-confirmed transthyretin amyloid polyneuropathy (ATTR‑PN) and peripheral neuropathy.
What is being studied AITests tafamidis meglumine soft capsules for neuropathy progression and safety in adults with transthyretin amyloid polyneuropathy.
Who can join AIAdults 18–75 who are asymptomatic carriers of a pathogenic or likely pathogenic TTR gene variant, without evidence of ATTR heart or nerve disease.
What is being studied AITests acoramidis versus placebo to prevent development of ATTR-CM or ATTR-PN.
Who can join AIAdults with cardiac light‑chain (AL) amyloidosis (age 18+), transthyretin (ATTR) cardiac amyloidosis (age 65+), or adults age 65+ without amyloidosis (controls).
What is being studied AIHigh-mechanical-index ultrasound with Definity plus PET and echocardiography to measure heart blood flow and function.
Who can join AIAdults 18–100 with suspected cardiac transthyretin (ATTR) amyloidosis and heart failure who meet specific imaging and biomarker criteria.
What is being studied AITests quantitative myocardial uptake of 99mTc bone tracers with CZT SPECT-CT.
Who can join AIAdults 18–80 with Charcot‑Marie‑Tooth type 1A, hereditary transthyretin amyloid neuropathy (ATTR‑PN), or acquired demyelinating neuropathy.
What is being studied AITests MRI and ultrasound biomarkers of muscle and nerve changes measured between baseline and one year.
Who can join AIPeople with wild-type or hereditary transthyretin (TTR) cardiac amyloidosis (ATTR‑CA) and age‑matched patients with non-amyloid hypertrophic cardiomyopathy.
What is being studied AIMeasures liver function, liver stiffness (FibroScan) and detailed coagulation tests in ATTR-CA and controls.
Who can join AIAdults (≥18) with confirmed transthyretin (ATTR) amyloidosis — including cardiomyopathy or polyneuropathy — who are in the D8450R00003 cohort.
What is being studied AICollects long-term safety and use data for eplontersen users, including liver transplant and severe hepatic impairment.
Who can join AIAdults with hypertrophic‑phenotype cardiomyopathies (including sarcomeric and non‑sarcomeric HCM, Anderson‑Fabry, and amyloid), their first‑degree relatives, and genetic carriers.
What is being studied AICompares CMR myocardial perfusion patterns across different hypertrophic cardiomyopathy phenotypes.
Who can join AIPeople with a heart transplant or various myocardial diseases (dilated or hypertrophic cardiomyopathy, myocarditis/pericarditis, cardiac amyloidosis, cardiac sarcoidosis).
What is being studied AICollects an extra endomyocardial biopsy for molecular and immune (multi-omics) analysis.
Who can join AIPeople aged ≥60 with non‑reduced LVEF heart failure or left ventricular hypertrophy (with or without ATTR‑CM), or control subjects without heart failure. The amyloid arm requires confirmed transthyretin (ATTR-CM) amyloidosis with AL amyloidosis ruled out.
What is being studied AICollects heart and liver shear wave velocity (SWV) measurements using an investigational ultrasound device.
Who can join AIPregnant or lactating individuals with an approved indication for eplontersen who were exposed to eplontersen, and infants linked to those exposures.
What is being studied AICollects and describes pregnancy, birth, and infant outcomes after eplontersen exposure.
Who can join AIPeople being evaluated for Alzheimer's disease, including those with Alzheimer's-type dementia, mild cognitive impairment, or cardiac amyloidosis.
What is being studied AIUses amyloid PET/MRI of the heart plus echo and clinical dementia exams.
Who can join AIPeople with cardiomyopathies and related heart conditions (for example hypertrophic, dilated, arrhythmogenic, cardiac amyloidosis, Fabry disease).
What is being studied AICollects clinical, imaging, genetic, and microRNA/spatial transcriptomic data to identify diagnostic and prognostic markers.
Who can join AIAdults with cardiomyopathies and related heart conditions — examples include hypertrophic cardiomyopathy, cardiac amyloidosis, sarcoidosis, and many others.
What is being studied AICollects CMR imaging and medical record data to study cardiomyopathy causes and outcomes.
Who can join AIAdults (age ≥18 to 130 years) with a confirmed diagnosis of transthyretin (ATTR) amyloidosis, including ATTR‑CM, ATTRv‑PN, mixed, and hereditary (hATTR) forms.
What is being studied AICollects real-world clinical, treatment, and outcome data including patients treated with eplontersen
Who can join AIAdults who had spinal decompression surgery for lumbar spinal stenosis in the past 20 years, at age 50 or older. People already diagnosed with transthyretin (TTR), AL or AA amyloidosis cannot join.
What is being studied AIChecks past spinal specimens for transthyretin amyloid and evaluates the heart for ATTR cardiac amyloidosis.
Who can join AIPeople who carry pathogenic TTR gene variants (including V122I), matched non‑carrier controls, and people with symptomatic V122I hATTR-CA.
What is being studied AIUses cardiac MRI and blood biomarkers to detect subclinical transthyretin cardiac amyloidosis.
Who can join AIPeople with hereditary or wild‑type ATTR (transthyretin) amyloidosis, and pre-symptomatic carriers of a known disease-causing TTR variant.
What is being studied AICollects long-term clinical and safety data on people with ATTR amyloidosis and pre-symptomatic carriers.
Who can join AIAdults aged 65 or older, or aged 50-64 with a family history of ATTR amyloidosis or a known TTR gene variant, who need a pacemaker, CRT or ICD and have at least one possible warning sign of cardiac amyloidosis.
What is being studied AICollects fat‑pad and heart biopsies during pacemaker implant to detect transthyretin cardiac amyloidosis.
Who can join AIPeople with confirmed or suspected cardiac amyloidosis (including heart failure) who are undergoing cardiac MRI and spectroscopic evaluation.
What is being studied AICollects cardiac MRI (resting and exercise), MR spectroscopy, exercise testing, and blood biomarkers over two years.
Who can join AIPeople with amyloidogenic transthyretin (ATTR) amyloidosis or cardiac amyloidosis.
What is being studied AITests whether evuzamitide PET-CT detects cardiac transthyretin amyloid in patients with unclear nuclear scans and elevated TAD1
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.
Who can join AIAdults with EMG-confirmed carpal tunnel syndrome scheduled for endoscopic carpal tunnel surgery; study compares biopsies for transthyretin amyloidosis detection.
What is being studied AIWhether ligament biopsy during endoscopic surgery agrees with synovial biopsy for transthyretin amyloidosis detection.
Who can join AIPeople aged ≥65 with heart failure with preserved ejection fraction (diastolic HF), being evaluated for transthyretin (ATTR) amyloidosis.
What is being studied AIUses a 99mTc-pyrophosphate (PYP) heart scan to detect transthyretin cardiac amyloidosis.
Who can join AIAdults who had carpal tunnel release surgery on both hands between 2010 and 2015, at age 55 or older, and have not been diagnosed with amyloidosis.
What is being studied AIPerforms Tc-99m PYP heart scans to detect cardiac transthyretin (ATTR) amyloid in people with bilateral CTS.
Who can join AIAdults (19+) with atrial fibrillation and at least one warning sign that could point to cardiac amyloidosis. People already diagnosed with cardiac amyloidosis cannot join.
What is being studied AIWhether AI-enhanced ECG and CT-derived extracellular volume can screen for concealed cardiac amyloidosis in AF patients.
Who can join AIPeople with severe aortic valve stenosis being evaluated for TAVI (transcatheter aortic valve implantation), some of whom may have suspected cardiac amyloidosis.
What is being studied AICollects imaging (echocardiography, CT, Tc99-SPECT/CT, CMR) to detect cardiac amyloidosis.
Who can join AIClinicians who order, perform, or interpret echocardiograms for adults with suspected genetic cardiomyopathy, ischemic cardiomyopathy/ischemic heart disease, cardiac amyloidosis, or hypertrophic cardiomyopathy.
What is being studied AITests AI analysis of transthoracic echocardiograms to flag specific heart diseases and assess workflow effects.
Who can join AIAdults with wild-type ATTR cardiac amyloidosis who are taking or about to start tafamidis 61 mg, with no history of atrial fibrillation or major heart-rhythm block.
What is being studied AITracks heart rhythm disturbances and diuretic dose in ATTRwt patients treated with tafamidis.
Who can join AIPeople with cerebral small vessel diseases such as cerebral amyloid angiopathy (CAA), hypertensive deep perforator arteriolopathy, or CADASIL.
What is being studied AITracks one-year risks of bleeding, stroke, death, cognition, and function in small vessel disease patients.